Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial - 14/07/19
, Pierre Ollitrault, MD c, Marc-Olivier Fischer, MD, PhD b, d, Jean-Luc Fellahi, MD, PhD e, Bertrand Rozec, MD, PhD f, Bernard Cholley, MD, PhD g, Charles Dolladille, MD a, c, Mathieu Chequel, MD c, Stéphane Allouche, MD, PhD b, h, Damien Legallois, MD b, c, Vladimir Saplacan, MD i, Dimitrios Buklas, MD i, Farzin Beygui, MD, PhD b, c, Jean-Jacques Parienti, MD, PhD j, k, Paul Milliez, MD, PhD b, cAbstract |
Background |
After artery bypass grafting (CABG), the presence of perioperative AF (POAF) is associated with greater short- and long-term cardiovascular morbidity. Underlying POAF mechanisms are complex and include the presence of an arrhythmogenic substrate, cardiac fibrosis and electrical remodeling. Aldosterone is a key component in this process. We hypothesize that perioperative mineralocorticoid receptor (MR) blockade may decrease the POAF incidence in patients with a left ventricular ejection fraction (LVEF) ≥50% who are referred for CABG with or without aortic valve replacement (AVR).
Study design |
The ALDOCURE trial (NCT03551548) will be a multicenter, randomized, double-blind, placebo-controlled trial testing the superiority of a low-cost MR antagonist (MRA, spironolactone) on POAF in 1500 adults referred for on-pump elective CABG surgery with or without AVR, without any history of heart failure or atrial arrhythmia.
The primary efficacy end point is the occurrence of POAF from randomization to within 5 days after surgery, assessed in a standardized manner. The main secondary efficacy end points include the following: postoperative AF occurring within 5 days after cardiac surgery, perioperative myocardial injury, major cardiovascular events and death occurring within 30 days of surgery, hospital and intensive care unit length of stay, need for readmission, LVEF at discharge and significant ventricular arrhythmias within 5 days after surgery. Safety end points, including blood pressure, serum potassium levels and renal function, will be monitored regularly throughout the trial duration.
Conclusion |
The ALDOCURE trial will assess the effectiveness of spironolactone in addition to standard therapy for reducing POAF in patients undergoing CABG.
Clinical trial registration |
NCT03551548
Le texte complet de cet article est disponible en PDF.Plan
| RCT# NCT03551548 |
Vol 214
P. 88-96 - août 2019 Retour au numéro
Article précédent
- Rationale and design of DanGer shock: Danish-German cardiogenic shock trial
- Nanna Junker Udesen, Jacob Eifer Møller, Matias Greve Lindholm, Hans Eiskjær, Andreas Schäfer, Nikos Werner, Lene Holmvang, Christian Juhl Terkelsen, Lisette Okkels Jensen, Anders Junker, Henrik Schmidt, Kristian Wachtell, Holger Thiele, Thomas Engstrøm, Christian Hassager, DanGer Shock investigators
- Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial)
- G. Toth, Marianne Brodmann, Emanuele Barbato, Fabio Mangiacapra, Laura Schneller, Viktor Orias, Robert Gil, Jacek Bil, Stanislaw Bartus, Zoltan Ruzsa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?